ArticlePurinergic signalling2026
Phenolic compounds and chemotherapeutic agents differentially regulate P2X receptor subtypes in malignant melanoma.
Article in Purinergic signalling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melanoma is an aggressive malignancy characterized by high metastatic potential and resistance to conventional therapies. Emerging evidence suggests that purinergic P2X receptors, particularly P2X7, play critical roles in regulating tumor cell proliferation, apoptosis, and invasion. However, the transcriptional regulation of P2X receptor subtypes in response to therapeutic compounds remains incompletely characterized. This study aimed to investigate the transcriptional modulation of all seven P2X receptor subtypes (P2XR1-7) in G361 melanoma cells following exposure to selected phenolic compounds and chemotherapeutic agents. Cell viability was evaluated by MTT assay, and half-maximal inhibitory concentrations (IC₅₀) were determined using non-linear regression analysis in GraphPad Prism software. Chemotherapeutic agents, including paclitaxel and sunitinib, exhibited strong cytotoxic effects under the experimental conditions employed, whereas phenolic compounds (quercetin, retinoic acid, and resveratrol) demonstrated moderate anti-proliferative activity. Quantitative real-time PCR analyses revealed compound-specific transcriptional response patterns. Quercetin induced upregulation across multiple P2X receptor subtypes, retinoic acid exhibited a partially suppressive profile, and resveratrol showed selective downregulation. In contrast, chemotherapeutic agents generally induced mRNA upregulation, particularly in P2XR4, P2XR5, and P2XR7 subtypes. These findings demonstrate that P2X receptor genes are differentially modulated at the transcriptional level by natural and synthetic compounds. The present work provides a transcriptional framework identifying subtype-specific response patterns and nominates candidate P2X receptors for future protein-level and functional validation studies in melanoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.